Language
English
Publication Date
8-7-2024
Journal
Molecular Therapy
DOI
10.1016/j.ymthe.2024.05.039
PMID
38822527
PMCID
PMC11405165
PubMedCentral® Posted Date
5-31-2024
PubMedCentral® Full Text Version
Post-print
Abstract
In recent years, the therapeutic landscape for hematological malignancies has markedly advanced, particularly since the inaugural approval of autologous chimeric antigen receptor T cell (CAR-T) therapy in 2017 for relapsed/refractory acute lymphoblastic leukemia (ALL). Autologous CAR-T therapy involves the genetic modification of a patient's T cells to specifically identify and attack cancer cells, while bispecific antibodies (BsAbs) function by binding to both cancer cells and immune cells simultaneously, thereby triggering an immune response against the tumor. The subsequent approval of various CAR-T therapies and BsAbs have revolutionized the treatment of multiple hematological malignancies, highlighting high response rates and a subset of patients achieving prolonged disease control. This review explores the mechanisms underlying autologous CAR-T therapies and BsAbs, focusing on their clinical application in multiple myeloma, ALL, and non-Hodgkin lymphoma. We provide comprehensive insights into their individual efficacy, limitations concerning broad application, and the potential of combination therapies. These upcoming strategies aim to propel the field forward, paving the way for safer and more effective therapeutic interventions in hematological malignancies.
Keywords
Humans, Antibodies, Bispecific, Hematologic Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes, Animals, Receptors, Antigen, T-Cell, Combined Modality Therapy
Published Open-Access
yes
Recommended Citation
Al Hadidi, Samer; Heslop, Helen E; Brenner, Malcolm K; et al., "Bispecific Antibodies and Autologous Chimeric Antigen Receptor T Cell Therapies for Treatment of Hematological Malignancies" (2024). Faculty and Staff Publications. 1559.
https://digitalcommons.library.tmc.edu/baylor_docs/1559
Included in
Immunotherapy Commons, Internal Medicine Commons, Medical Sciences Commons, Oncology Commons